EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

“Ondansetron augmentation for obsessive–compulsive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials”

Anas Mohammad, Mohammad Ibrahim, Aneeq Mahmood Khan, Usama Pervaiz, Sarah Aijaz, Muhammad Hassnain Nasrullah, Hammad Jamil

European Journal of Clinical Pharmacology · 2026

DOI: 10.1007/s00228-026-04085-9 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Anas Mohammad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Sargodha Medical College, Ibn E Sina Hall 1, Boys Hostel, Sargodha, 40100, Pakistan. anastahir192@gmail.com. Hauptthemen laut MEDLINE: Ondansetron, Obsessive-Compulsive Disorder, Serotonin 5-HT3 Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A substantial proportion of adults with obsessive-compulsive disorder (OCD) experience persistent symptoms despite optimized first-line treatment with exposure and response prevention and/or serotonin reuptake inhibitors (SRIs). Ondansetron, a selective 5-hydroxytryptamine-3 (5-HT3) receptor antagonist with plausible circuit-level relevance to cortico-striato-thalamo-cortical dysfunction, has been evaluated as an augmentation strategy. Still, evidence is dispersed across small randomized trials. METHODS: We conducted a PRISMA 2020-adherent systematic review and random-effects meta-analysis (PROSPERO: CRD420261302132). Embase (Ovid and Embase.com), MEDLINE, PubMed, and Scopus were searched from inception to 12 February 2026. Eligible studies were randomized, double-blind, placebo-controlled trials of oral ondansetron augmentation in adults (≥ 18 years) with OCD on stable background treatment. The primary outcome was change in Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) total score, pooled at prespecified acute windows (week 4, ~week 8 primary, week 12). Secondary outcomes included Y-BOCS obsession and compulsion subscales. Risk of bias was assessed using RoB 2. Random-effects models (DerSimonian-Laird) were used; Wan's method was applied when required. RESULTS: Five trials (total N = 289) were included. Ondansetron augmentation was associated with greater improvement in Y-BOCS total score versus placebo at week 4 (MD 2.63; 95% CI 0.87-4.39; I²=62%); heterogeneity resolved after excluding one influential study (MD 1.94; 0.37-3.51; I²=0%). At week 8 (four trials; N = 244), benefit was larger (MD 5.53; 3.45-7.60; I²=48%) and remained robust in sensitivity analysis (MD 6.76; 5.81-7.71; I²=0%). At week 12 (three trials; N = 200), effects persisted (MD 6.41; 4.28-8.53; I²=55%) with reduced heterogeneity after excluding one study (MD 5.06; 2.82-7.30; I²=0%). In two trials reporting subscales (N = 214), obsessions improved at weeks 4 and 8 (overall MD 2.67; 1.66-3.67; I²=0%), while compulsions showed a smaller, later signal (overall MD 1.02; 0.19-1.86; I²=0%). Safety reporting was variably detailed across trials; known QT-prolongation considerations remain relevant for off-label use. CONCLUSIONS: In randomized, placebo-controlled trials, ondansetron augmentation was associated with greater improvement in clinician-rated OCD severity than placebo over short-term follow-up, with signals emerging by week 4 and persisting through 8-12 weeks. However, these findings should be interpreted cautiously because the evidence base is small, geographically concentrated, and partly influenced by individual studies. The current evidence should therefore be considered preliminary and hypothesis-generating rather than definitive. Larger multicenter trials with standardized background SRI optimization, preregistered outcomes, and rigorous safety monitoring are required before routine clinical adoption can be considered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OndansetronObsessive-Compulsive DisorderSerotonin 5-HT3 Receptor AntagonistsHumansRandomized Controlled Trials as TopicDrug Therapy, Combination

Stichwörter der Autor:innen

5-HT3 receptor antagonistAugmentationMeta-analysisObsessive–compulsive disorderOndansetronRandomized controlled trials

Substanzen

OndansetronSerotonin 5-HT3 Receptor Antagonists

Autor:innen und Institutionen

  • Sargodha Medical College, Ibn E Sina Hall 1, Boys Hostel, Sargodha, 40100, Pakistan. anastahir192@gmail.com.
  • Shaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore, Pakistan.
  • Sargodha Medical College, Ibn E Sina Hall 1, Boys Hostel, Sargodha, 40100, Pakistan.
  • United Medical and Dental College, Karachi, Pakistan.
  • Jinnah Hospital, Lahore, Pakistan.

Zitieren

APA

Mohammad, A., Ibrahim, M., Khan, A. M., Pervaiz, U., Aijaz, S., Nasrullah, M. H., & Jamil, H. (2026). “Ondansetron augmentation for obsessive–compulsive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials”. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04085-9

Vancouver

Mohammad A, Ibrahim M, Khan AM, Pervaiz U, Aijaz S, Nasrullah MH, et al. “Ondansetron augmentation for obsessive–compulsive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials”. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-026-04085-9

BibTeX
@article{Mohammad2026,
  author = {Mohammad, Anas and Ibrahim, Mohammad and Khan, Aneeq Mahmood and Pervaiz, Usama and Aijaz, Sarah and Nasrullah, Muhammad Hassnain and Jamil, Hammad},
  title = {“Ondansetron augmentation for obsessive–compulsive disorder: A systematic review and meta-analysis of randomized placebo-controlled trials”},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1007/s00228-026-04085-9}
}
Kostenlos starten →